akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Tuesday, April 19, 2016

Company News: ISA Pharmaceuticals obtains broad patent protection in the US for proprietary AMPLIVANT® platform and compounds

- Granted US patent provides market exclusivity until 2032

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a US patent on its AMPLIVANT® technology and compounds (patent no. 9,314,521). The patent ensures market protection in the United States until 2032 and covers the compounds, either as a stand-alone substance or in combination with antigenic peptides, nucleic acids or antibodies. The patent also covers the process for preparing the compounds.

Thursday, April 14, 2016

Company News: ISA Pharmaceuticals’ Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions

- ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer

- Optimum immunotherapy window in cancer identified

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication of two peer-reviewed research manuscripts demonstrating the clinical efficacy of its lead product ISA101 in treating high-grade vulvar intraepithelial neoplasia (VIN), and synergy with chemotherapy in cervical cancer. In cervical cancer, the optimum window for treatment with ISA101 starts two weeks after the second chemotherapy cycle has been completed. The multi-center research was conducted in close collaboration with Leiden University Medical Center (LUMC). Publications appeared in Clinical Cancer Research[1] and Science Translational Medicine[2], respectively.